AVXS AveXis, Inc.

52.61
-0.76  -1.42%
Previous Close 53.37
Open 53.68
Price To book 5.52
Market Cap 1.46B
Shares 27,676,000
Volume 485,886
Short Ratio 4.96
Av. Daily Volume 571,136

SEC filingsSee all SEC filings

  1. 8-K - Current report 17515994
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 162069130
  3. 8-K - Current report 162064020
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161988159
  5. 8-K - Current report 161988025

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 ongoing. Data due 1Q 2017. Pivotal trial to be initiated 1H 2017.
AVXS-101
Spinal muscular atrophy (SMA) Type 1

Latest News

  1. Hurry! These 5 Stocks Are About to Break Out Explosively
  2. AVEXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  3. AveXis to Present at the 35th Annual J.P. Morgan Healthcare Conference
  4. Top Analyst Upgrades and Downgrades: Biogen, Comerica, Deere, NVIDIA, 21st Century Fox and More
  5. Avexis Inc. (AVXS): RA Capital Management Ups Its Stake
  6. AveXis to Use Intended Commercial GMP Product in SMA Type 2 Study
  7. AVEXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  8. AveXis to Use Intended Commercial GMP Product in SMA Type 2 Study
  9. 3 Reasons Biogen Inc. Stock Is Set to Soar in 2017
  10. Citron Research On AveXis: This Will Be One Of 2017's Biotech Blowups
  11. Do Hedge Funds Love ClubCorp Holdings Inc (MYCC)?
  12. 3 Things You Need to Know About Ionis Pharmaceuticals' Pipeline
  13. AVEXIS, INC. Financials
  14. Coverage initiated on AveXis by Stifel
  15. AveXis Reports Third Quarter 2016 Financial and Operating Results
  16. AVEXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  17. AveXis Reports Third Quarter 2016 Financial and Operating Results
  18. Drug Stocks Surge on Trump Win: 5 Stocks to Buy Now
  19. Q3 2016 AveXis Inc Earnings Release - After Market Close
  20. Should You Sell AveXis (AVXS) Before Earnings?

SEC Filings

  1. 8-K - Current report 17515994
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 162069130
  3. 8-K - Current report 162064020
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161988159
  5. 8-K - Current report 161988025
  6. SC 13G - Statement of acquisition of beneficial ownership by individuals 161986756
  7. 8-K - Current report 161964863
  8. 8-K - Current report 161931397
  9. 424B4 - Prospectus [Rule 424(b)(4)] 161881170
  10. S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)] 161874671